Bristol-Myers Squibb execs and Starboard Value are back at it today, exchanging broadsides for and against the $74 billion buyout.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,